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Abstract 
Background: S100A11 is a member of the S100 family of proteins containing two EF-hand calcium-binding motifs. 
The dysregulated expression of the S100A11 gene has been implicated in tumour metastasis. However, the role of 
S100A11 protein in tumour cell response to chemotherapeutic drugs has not been characterised.
Methods: Transcript levels of S100A11 in gastric cancer were evaluated using an in-house patient cohort. Protein 
expression of S100A11 in gastric cancer was estimated by immunohistochemistry of a tissue microarray. The stable 
gastric cancer cell lines were established using lentiviral shRNA vectors. The knockdown of S100A11 was validated by 
qRT-PCR, PCR, and Western blot. The cellular function of S100A11 was estimated by assays of cell adhesion, migra-
tion, and invasion. The cell cytotoxic assay was performed to investigate the response to chemotherapeutic drugs. An 
unsupervised hierarchical clustering and principal component analysis (HCPC) was applied to unveil the dimensional 
role of S100A11 among all S100 family members in gastric cancer.
Results: High expression of S100A11 is associated with poor survival of gastric cancer patients (p < 0.001, HR = 1.85) 
and is an independent prognostic factor of gastric cancer. We demonstrate that S100A11 plays its role as a tumour 
promoter through regulating the MMP activity and the epithelial-mesenchymal transition (EMT) process. The stable 
knockdown of S100A11 suppresses the metastatic properties of gastric cancer cells, which include enhancing cell 
adhesion, but decelerating cell migration and invasion. Furthermore, the knockdown of S100A11 gene expression 
dramatically induces the cellular response of gastric cancer cells to the first-line chemotherapeutic drugs fluoropy-
rimidine 5-fluorouracil (5-FU) and cisplatin.
Conclusion: The present study identifies S100A11 as a tumour promoter in gastric cancer. More importantly, the 
S100A11-specific targeting potentially presents dual therapeutic benefits by not only controlling tumour progression 
but also sensitising chemotherapeutic cytotoxic response.
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Background
Gastric cancer (GC) is ranked as the fifth of the most 
common malignant tumours and the third lead-
ing cause of cancer-related death in the world [1, 2]. 
Because most patients lack specific symptoms in the 
early stage of GC, they are dominantly diagnosed with 
an advanced tumour that presents with metastasis, 
often missing the optimal operation time and possess-
ing poor prognosis outcome. Accumulating data show 
that the median survival for patients with metastatic 
gastric cancer ranges from only 3 to 5 months [3–5]. To 
date, palliative systemic therapy is the optimal choice 
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to drugs is different among distinct patients. Moreo-
ver, chemoresistance is one of the main clinical chal-
lenges, which limits the efficiency of chemotherapy and 
often leads to treatment failure. Presently, most of the 
chemotherapy regimens usually induce DNA damage 
and trigger apoptosis leading to cell death [6]. How-
ever, tumour cells could increase DNA repair ability 
and deregulate apoptosis signaling pathways to resist 
the therapy response induced by the drugs. Therefore, 
enhancing apoptosis is an important approach to sen-
sitise tumour response to chemotherapies and con-
trol tumour progression. Some molecules have been 
described to coordinate with drugs and positively reg-
ulate cell apoptosis upon chemotherapy, which may 
affect tumour resistance and improve the therapeutic 
efficiency to combat cancer.
S100A11, also named calgazzarin, is a member of the 
S100 family which belongs to calcium-binding proteins 
with two EF-hands [7]. S100A11 protein is a small molec-
ular weight (13  kDa) acidic protein and shows altered 
expression in various solid tumours, including lung can-
cer [8], colorectal cancer [9], pancreatic cancer [10] and 
prostate cancer [11]. S100A11 protein plays a broad role 
in intracellular and extracellular biological functions, 
such as cell differentiation, cell cycle, cell apoptosis, cell 
proliferation, cell migration and invasion [12, 13]. Addi-
tionally, the S100 family has been demonstrated to have 
a link with cancer stem cells, which play crucial roles in 
maintaining self-renewal or cancer stem-like proper-
ties [14]. An increasing number of papers have reported 
that S100A11 behaves as a tumour promoter in prostate, 
pancreatic, breast, ovarian and colorectal carcinoma, but 
inhibits tumour progression in bladder cancer [9, 11, 15–
18]. The translocation of S100A11 from the cytoplasm 
to the nucleus, induced by DNA damage, could increase 
the protein level of p21 and regulate the cell cycle [19]. 
S100A11 knockdown in non-small cell lung cancer 
induces a strong potential ability of apoptosis upon 
treatment with chemotherapy drugs [20]. Furthermore, 
S100A11 has previously been shown to interact with 
many target proteins, which lead to cancer initiation and 
progression, such as RAGE, Annexin family, p21/WAFI, 
p53 and other S100members [21–25].
In the present study, we demonstrate that S100A11 
displays higher expression in GC tissues compared to 
adjacent normal tissues and leads to poor survival in 
GC patients. S100A11 promotes GC cell migration and 
invasion via inducing EMT and MMPs. Furthermore, we 
show for the first time that knockdown of S100A11 in 
GC cell lines results in the strong induction of apoptosis 
upon treatment with cisplatin or 5-fluorouracil, suggest-
ing that S100A11 represents promising therapeutic tar-
gets to combat GC, or performs as a potential molecular 
marker to predict the effectiveness of chemotherapy of 
GC.
Materials and method
Cell lines and cell culture
AGS and HGC27 human gastric cancer cell lines were 
obtained from the European Collection of Animal Cell 
Cultures (ECACC, Salisbury, UK). The cells were cultured 
with Dulbecco’s modified Eagle’s medium (DMEM)-F12 
medium containing 10% fetal calf serum (FCS) and anti-
biotics which was named as a normal medium, and main-
tained in a 5%  CO2 incubator at 37 °C.
Patients and human GC tissue
A total of 324 GC specimens along with matched adja-
cent normal gastric tissues from GC patients, who were 
diagnosed and surgically treated at Peking University 
Cancer Hospital over a period from 2004 to 2007 with 
follow-up information up to 2012, were included in 
this study. In addition, another 87 pairs of GC and cor-
responding adjacent normal tissues collected from GC 
patients, who had been treated with perioperative chem-
otherapy between 2006 and 2007, were analyzed to detect 
the relationship between S100A11 and chemotherapy 
resistance. All the tissues were stored immediately after 
surgery at − 80  °C or subjected to RNA isolation. Clin-
icopathological factors were recorded and stored in the 
patient database. GC stage was classified according to the 
2010 tumor-node-metastasis (TNM) classification rec-
ommended by the American Joint Committee on Can-
cer (AJCC 7th edition). All patients signed an informed 
consent form, and the study was approved by the Ethics 
Committee of Peking University Beijing Cancer Hospital.
Lentiviral vector transduction of GC cells 
for stable S100A11 knockdown
Lentivirus plasmids containing a short hairpin RNA 
(shRNA)for S100A11and its negative control were pur-
chased from Vector Builder (Vector Builder, Cyagen Bio-
sciences, Santa Clara, USA). Lentivirus was produced 
by the co-transfection of 293  T cells with a pLenti vec-
tor (pLV-shControl or pLV- shS100A11) and lentiviral 
packaging mix (psPAX2 packing plasmid and pMD2.G 
envelope plasmid), according to the manufacturer’s 
instruction. Lentivirus-containing supernatant was 
harvested at 24 and 48  h post-transfection, filtered and 
stored at − 80 °C. Briefly, viral particles were added into 
AGS and HGC27 cells with 8 µg/ml Polybrene for 24 h, 
and then the fresh medium was changed. After incuba-
tion for another 24  h, the infected cells were subjected 
to a selection medium with 2 μg/ml puromycin. Finally, 
stable silencing S100A11GC cells were maintained in a 
medium with 0.6 μg/ml puromycin.
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RNA isolation, reverse transcriptional PCR, conventional 
polymerase chain reaction (PCR)
Total RNA was isolated separately from GC cells and 
frozen tissues using TRI reagent (Sigma-Aldrich), and 
one-step reverse transcribed into cDNA using Pro-
mega Reverse Transcription kit (Promega, Dorset, UK) 
according to the manufacturer’s instructions. PCR was 
performed on SimpliAmp Thermal Cycler (Applied Bio-
systems, Paisley, UK) using GoTaq Green MasterMix 
(Promega, Dorset, UK) in a final volume of 16 μl. GAPDH 
was used as an endogenous control for each sample and 
the PCR products were visualized using 1.5% agarose gels 
stained with SYBR Safe (Invitrogen).
Transcript quantification of S100A11 in GC cells and GC 
tissues by quantitative real‑time PCR (qPCR)
S100A11expression in GC cells and tissues was detected 
by qPCR, which was run on the StepOne Plus Real-Time 
PCR System (Applied Biosystems, Paisley, UK), and per-
formed with a Precision FAST 2X qPCR MasterMix 
(Primer Design Ltd., Chandler’s Ford, UK) in a final vol-
ume of 10  µl, using GAPDH or β-actin as an internal 
control. Reaction conditions were as follows: 94  °C for 
10 min, followed by 100 cycles of 94 °C or 10 s, 55 °C for 
30  s and 72  °C for 10  s. The primer sequences used for 
PCR and qPCR are listed in Additional file 4: Table S1.
Western blot analysis
Cells were washed by ice-cold PBS twice, and extracted 
by RIPA buffer with protease inhibitor and phosphatase 
inhibitor. Protein concentration was qualified by DCTM 
protein assay kit (Bio-Rad, Laboratories, Hemel-Hemp-
stead, UK). Thirty μg of each protein sample was trans-
ferred onto a 0.45  μm polyvinylidenedifluoride (PVDF) 
membrane (Millipore, Billerica, MA) after separation 
by 10 or 12% sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis (SDS-PAGE). The membrane was 
blocked with 5% nonfat milk for 1 h at room temperature, 
then incubated in primary antibody (1:500) at 4 °C over-
night and secondary antibody (1:2000) for 1  h. The pri-
mary antibodies were S100A11, cleaved PARP (detecting 
both full-length and cleaved PARP) (eBioscience Inc., San 
Diego, CA, USA); p21WAF1, p53 (DO-1) and GAPDH 
(Santa Cruz Biotechnology, Inc., Santa Cruz, USA). The 
results shown are representative of three independent 
experiments.
Conditioned medium
Cells were cultured in T25 flasks with a normal medium. 
At 70–80% confluence, cells were washed twice with PBS 
and continued to incubate in a serum-free medium. After 
48  h, the conditioned medium was collected and con-
centrated by Amicon® Ultra-4 Centrifugal Filter Devices 
(50 kDa, Sigma-Aldrich) before use or stored at -80 °C.
Treatment with Cisplatin and 5‑fluorouracil (5‑FU)
When reaching 70–80% confluence, cells were changed 
into serum-free medium and cultured for 4–6  h, then 
treated with chemotherapeutic drugs as follows: 20  μM 
cisplatin and 38 μM 5-fluorouracil for 24 h, followed by 
Western Blot and FACS analysis. For caspase-3/7 activ-
ity investigation, cells were treated with 6.25 μM cisplatin 
and 19 μM 5-fluorouracil for 24 h.
Colony assay
Transfected GC cells were seeded into 6-well plates at 
400 cells/ well and treated with 2 μM Cisplatin or 19 μM 
5-fluorouracil for 24  h. After the treatment, the growth 
medium was replaced with a fresh medium without 
drugs, and cells were cultured for two weeks. Colonies 
derived from cells were subsequently fixed in 4% forma-
lin for 30 min and stained with 0.5% (w/v) crystal violet 
(Sigma-Aldrich, St. Louis, MO, USA) for 15  min. The 
excessive crystal violet was removed using double-dis-
tilled  H2O. After the stained colonies were photographed, 
they were completely dissociated in 10% (v/v) acetic acid. 
The densities of the stained and dissolved colonies were 
then qualified by measuring the absorbance at 540  nm 
using a spectrophotometer (Elx800; Bio-Tek, Bedford-
shire, UK).
Cell matrix adhesion assay
Ten micrograms of Matrigel® Basement Membrane 
Matrix (Corning Incorporated, Flintshire, UK) were used 
to coat each well of a black 96-well plate. A total of 2 × 
104 cells were seeded into each well and incubated for 
1 h. Then cells were washed twice by PBS and stained by 
dissociation solution (CDS; Sigma-Aldrich)/calcein-AM 
Viability Dye (eBioscience Inc., San Diego, CA, USA) at 
a ratio of 1.2  μl calcein-AM in 1  ml CDS (100  μl/well) 
for 30  min. The suspension was read on a GLOMAX® 
MULTI Detection System (Promega, Dorset, UK) at 
495  nm excitation and 519  nm emission and images of 
the cells were taken using 4 × EVOS FL Auto (Life Tech-
nologies). The results were expressed as a fold change of 
the adherent cell number compared to the lowest value.
Cell invasion assay
An 8  μm-pore ThinCert™ 24-well plate insert (Greiner 
Bio-One, Gloucester, UK), previously coated with 100 μg 
of Matrigel® Basement Membrane Matrix (Corning 
Incorporated, Flintshire, UK), was used for evaluating the 
cell invasion. Following this, 5 ×  104 cells were seeded 
in the upper chamber in serum-free medium, and the 
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bottom chamber was filled with DMEM containing 10% 
FCS. After 24 h of incubation, the chamber was washed 
gently with PBS and incubated for one hour in 350 μl of 
dissociation solution/calcein-AM Viability Dye follow-
ing the method described above. Then the cell suspen-
sion was aliquoted into a black 96-well plate and read on 
a GLOMA® MULTI Detection System and images were 
taken of the invasive cell groups using 4 × EVOS FL Auto 
(Life Technologies).
Cell migration assay
Cell migration was assessed with a wound-healing assay. 
Cells were seeded into a 24-well plate at a density of 6 × 
 105 per well and then scratched to create a wound with 
a pipette tip after cells had formed a monolayer. The 
wound width was detected using a microscope at 0, 2, 
4, 6, 8 and 10 h, and migration distances were measured 
using Image J software (www. ImageJ. net).
In addition, an electric cell-substrate impedance sens-
ing (ECIS)-Zθ instrument (Applied Biophysics Ltd.; 
Troy, NJ, USA) was used to monitor cell migration, as 
described previously [26]. Briefly, 6 ×  104 cells, diluted 
in DMEM with 10% FCS, were seeded into each well 
of ECIS 96-plate arrays. Wounding was carried out by 
applying electric current (3000 μA, 60 kHz) once a con-
fluent monolayer had formed. The migration data were 
collected continuously for 12 h.
Measurement of caspase 3/7 activity
Cells were transfected as above and loaded into a white 
wall 96-well plate at a density of 5 ˣ  103 per well. After 
being starved for 4–6 h in serum-free DMEM, cells were 
treated with Cisplatin and 5-FU at the indicated concen-
tration for 24 h, while DMSO or PBS was used as a con-
trol. Then the levels of caspase-3/7 activity were assessed 
using a Caspase-Glo® 3/7 Assay (Promega) according 
to the manufacturer’s instructions. The luminescence of 
each sample was read on a GLOMA® MULTI Detection 
System.
Kinexus™ protein microarray
The stable gastric cancer cell lines containing S100A11-
kd or Scr were cultured in T75 flasks until reaching 
approximately 80% confluence followed by 2% FCS 
medium for 24  h before protein extraction. Cells were 
washed by iced-PBS twice and lysed in a lysis buffer con-
taining 100 mM tris, 10% 2-mercaptoethanol, 1% NP-40, 
50  mM NaFI, 2  mM 4-(2-aminoethyl) benzenesulfonyl 
fluoride, 14 μM E-64, 130 μM bestatin, 1 μM leupeptin, 
0.3 μM aprotinin and 1 mM EDTA. The cell lysates were 
delivered for the Kinexus™ antibody microarray analysis 
(Kinexus Bioinformatics, Vancouver, British Columbia, 
Canada) in dry ice to determine global signalling events.
Flow cytometric analysis
For protein expression analysis, cells were fixed with 
IC Fixation Buffer (eBioscience Inc. San Diego, USA) 
in the dark at room temperature for 30  min, and then 
incubated in ice-cold 100% methanol at 4 °C for 30 min. 
After blocking in 1% BSA in PBS, cells were incubated 
in PE-conjugated cleaved PARP1 antibody (1:40, eBio-
science Inc. San Diego, USA) overnight at 4  °C. In par-
allel, a mouse PE-conjugated IgG2b K Isotype antibody 
(1:10,000, eBioscience Inc. San Diego, USA) was used as a 
control. The next day, samples were washed by PBS twice 
and detected by using a BD CANTO II flow cytometer 
(BD Bioscience).
Hierarchical Clustering on Principal Components (HCPC) 
multivariate analysis
An unsupervised approach of hierarchical clustering and 
principal component analysis was performed using the 
R programming language version 4.0.3 (https:// www.r- 
proje ct. org) with packages of FactoMineR [27] and Facto-
extra [28]. The transcript expression data of all the S100 
family members in gastric cancer were extracted from 
TCGA.
Statistical analysis
All statistical analyses were performed using R program-
ming language or GraphPad Prism 6.0 (GraphPad Soft-
ware, La Jolla, CA, USA). The results were expressed as 
mean ± standard deviation (SD) of three independent 
experiments. The overall survival curve was drawn by the 
Kaplan–Meier plots and a log-rank test was used to esti-
mate the difference between groups. Statistical evalua-
tion was performed using Student’s t-test if data followed 
a normal distribution or Mann–Whitney U-test if data 
did not follow a normal distribution. A p-value less than 
0.05 was considered statistically significant.
Results
Clinical relationship of the S100A11 transcript and GC
We first determined the gene expression level of S100A11 
by qPCR in GC tissues collected from an in-house cohort 
of patients. As shown in Table  1, S100A11 expression 
exhibited significantly higher in GC tissues than adja-
cent normal tissues (P < 0.0001). However, we did not 
observe any statistical significance from GC groups with 
advanced tumour infiltration (T3 + T4) or TNM stages 
(TNM III + IV).
We then conducted the survival analysis of S100A11 
in GC using the KMplot dataset (https:// kmplot. com/ 
analy sis). As shown in Fig.  1a-c, the gene expression of 
S100A11 was negatively associated with overall survival 
(OS) (HR = 1.85 (1.56–2.20), logrank P < 0.0001), post-
progression survival (PPS) (HR = 2.37 (1.9–2.96), logrank 
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P < 0.0001) and first progression survival (FP) (HR = 1.98 
(1.61–2.43), logrank P < 0.0001). The differential expres-
sion analysis of the TCGA stomach adenocarcinoma 
(STAD) data (https:// www. cancer. gov/ tcga) indicated 
that the gene expression level of S1000A11 was higher in 
the tumour tissues than in the normal ones (p < 0.0001. 
Figure  1d). There was no significance observed among 
other clinicopathological features including M status, T 
stages, and sex (Fig. 1e-h).
Expression of S100A11 protein in GC tissues
We then evaluated the expression of the S100A11 protein 
in GC tissues by immunohistochemistry. The thumbnail 
image of the tissue array after staining with the S100A11 
is shown in Fig. 2a. It showed that the high intensity (2 
and 3) of the S100A11 staining occurred more frequently 
in malignant and metastatic (MET) tumour tissues 
than in the normal adjacent (NAT) and normal stom-
ach tissues (Fig. 2b). Further, a higher percentage of the 
high intensity of the S100A11 appeared in later stages 
(Stage >  = 2) of the tissues (Fig. 2c). The high intensity of 
the S100A11 staining was observed more in the higher 
grade tumour tissue as well (Fig. 2d). Taken together, the 
immunohistochemistry data demonstrate that S100A11 
protein is expressed at higher levels in tumour tissue with 
stage and grade dependence.
Effect of S100A11 on epithelial‑mesenchymal transition 
(EMT) and matrix metalloproteinase (MMPs) molecules 
in GC cells
To elucidate the function of S100A11, we knocked down 
this gene in gastric cancer cells and validated the knock-
down efficiency by qPCR and Western blotting (Fig. 3a–
c). Interestingly, we noticed that S100A11 can be secreted 
into the conditioned medium and the expression of 
secreted S100A11 was decreased in S100A11-silencing 
cells (Fig. 3d).
EMT is a process in which epithelial cells acquire mes-
enchymal, fibroblast-like properties and show reduced 
intercellular adhesion, critical for invasive and metastatic 
progression in cancer. Here, we found that S100A11 
depletion resulted in an upregulation of E-cadherin, 
and downregulation of N-cadherin, Snail and Slug mol-
ecules in both cell lines, whilst Vimentin decreased only 
in AGS cells with S100A11-kd. Moreover, we detected 
MMP expression and noticed that MMP2 and MMP3 
were depressed in both cell lines, while MMP9 slightly 
increased in the S100A11-kd AGS cells compared to the 
control (Fig. 3e). Therefore, S100A11 may promote inva-
sion and migration of GC cells by inducing EMT and 
MMP production.
To understand whether there is an intrinsic relation-
ship of S100A11 with the EMT and MMP markers, we 
conducted the correlation analysis using the TCGA 
STAD RNA-Seq dataset, as shown in Fig.  3f, in GE tis-
sues. S100A11 was positively correlated with E-cadherin 
(R = 0.13, p < 0.05), while negatively correlated with 
N-cadherin (R = − 0.23, p < 0.0001). There was no signifi-
cant correlation between S100A11 and other markers.
Knockdown of S100A11 enhances cell adhesion 
but decelerates the migration and invasion of gastric 
cancer cells
Next, we performed a series of functional assays in AGS 
and HGC27 cells to determine the role of S100A11 in 
gastric tumourigenesis. In vitro cell–matrix adhesion was 
used to detect the effect of S100A11 knockdown on the 
adhesive ability of GC cells to the extracellular matrix. A 
Table 1 The relationship between S100A11 transcript 
expression and the clinicopathological features in gastric cancer. 
Mann-Whitney U-test was used to compare the difference 
between two groups
Bold value indicate P value less than 0.05 was considered statistically significant
§ The missing clinical samples were excluded
N Median P
Tissue
 Tumor 237§ 580  < 0.0001
 Normal 292§ 0
Sex
 Male 175 621 0.8394
 Female 62 368
Depth of invasion
 T1 + T2 25 735 0.6443
 T3 + T4 205 567
Lymph node status
 N0 48 452 0.4236
 N1 + 2 + 3 185 589
Distance metastasis
 M0 200 574 0.167
 M1 36 572
TNM staging
 TNM1 + 2 54 452 0.5954
 TNM3 + 4 175 589
Differentiation
 Diff-H 1 232.84
 Diff-HM 5 3531
 Diff-M 46 475 0.0901
 Diff-ML 55 947 0.1726
 Diff-L 101 327 0.0565
Clinical outcome
 Alive 92 742 0.5648
 Died 144 384
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significant increase of cell–matrix adhesion was observed 
in AGS and HGC27 GC cells after S100A11 knock-
down (P = 0.0013 and P = 0.0106, respectively, Fig.  4a, 
b). Furthermore, the knockdown of S100A11 suppressed 
the migration in HGC27 cells compared to controls, but 
there was no difference in AGS cells (Fig. 4c–f). Besides, 
1.6e-10
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Fig. 1 Association of S100A11 gene expression with the survival and clinical features of gastric cancer patients. The survival analysis of S100A11 
(probe_ID: 200660_at) was conducted on the KMPlot (https:// kmplot. com). a Overall survival (OS). b Post progression survival (PPS). c First progress 
survival (FP). The association of S100A11 and the clinicopathological features of GC was analysed using the TCGA data. d Tumour vs normal. e 
Metastasis status. M0: no metastasis; M1: with metastasis. Mx: unknown metastasis status. f Lymph node metastasis stages. g Tumour stages. h 
Gender. The difference between the two groups was analysed using the Wilcoxon test, while the Kruskal–Wallis test was used to compare the 
difference among multiple groups
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the knockdown of S100A11 in both AGS and HGC27 
cells reduced the cellular invasive ability compared to 
their respective controls (P = 0.0195 and P = 0.0017, 
respectively, Fig.  4g, h). The data, therefore, demon-
strated that S100A11 plays a role in promoting migration 
and invasion in GC cells.
Knockdown of S100A11 attenuates chemotherapy 
resistance in GC cells
We then investigated whether S100A11 knockdown 
contributed to chemotherapy resistance. We performed 
a cell colony array to evaluate the effect of S100A11 on 
cellular response to cisplatin and 5-FU resistance. As 
shown in Fig. 5a, b, there was a significant decrease in cell 
colony formation in the S100A11-knockdown groups. 
Such decreases in drug resistance were accompanied by 
the significant increase of cell apoptosis in the S100A11-
kd AGS and S100A11-kd HGC27 cells after the treat-
ment with cisplatin or 5-FU for 24 h, as indicated by the 
increased level of cleaved PARP via FACS and Western 
blot (Fig.  5c–f). Moreover, S100A11 downregulation 
resulted in a significant increase of caspase-3/7 activity in 
GC cells after treatment with cisplatin and 5-FU (Fig. 5g, 
h). We also noticed that S100A11 knockdown induced 
p21 and p53 protein expression in AGS cells compared 
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Fig. 2 Immunohistostaining of S100A11 protein in gastric cancer tissue microarray. a The thumbnail image of the immunohistostaining of the 
GC tissues using a specific S100A11 antibody. The staining intensity was categorised into 4 levels: 0 negative; 1 weak; 2 intermediate; 3 strong. b 
Stacked frequency plot of the tumour types. MET, metastasis; NAT, normal adjacent tissue; c Stacked frequency plot of the tumour stages. d Stacked 
frequency plot of the tumour grades
















































































































































































Fig. 3 Effect of the knockdown of S100A11 on the regulation of EMT and MMP markers. The stable gastric cancer cells following the S100A11 
knockdown were validated using qRT-PCR in AGS cells (a), HGC27 cells (b) and Western blotting (c). d The reduction of the secreted S100A11 
protein in the culture medium indicated by Western blotting using the cellular lysate as a control. e Quantification of EMT and MMP markers in 
cells by semi-quantitative RT-PCR. f The correlation analysis of the transcript expression levels of S100A11 with EMT and MMP genes using the 
TCGA-STAD dataset
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Fig. 4 Effect of the S100A11 knockdown on adhesion, migration and invasion of gastric cancer cell lines. a Adhesion of the AGS cell lines with 
representative images beneath. b Adhesion of the HGC27 cell lines. c The migration analysis of the AGS cell lines using the wound healing assay. 
d The migration analysis of the HGC27 cell lines using the wound healing assay. e Representative images of the stable AGS cell lines during the 
wound healing assay. The red lines highlight the wound gap. f Representative images of the stable HGC27 cell lines during the wound healing 
assay. g Invasion analysis of the AGS cell lines. h Invasion analysis of the HGC27 cell lines
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Fig. 5 Role of S100A11 in the cellular response to therapeutic drugs. Effects of the S100A11 knockdown on colony formation in response to 
cisplatin and 5-Fu were evaluated in the stable AGS (a) and HGC27 (b), respectively. The representative images of colony formation are shown at the 
bottom. The change of the apoptosis levels indicated by FACS-based cleaved PARP in the stable AGS (c) and HGC27 cells (d), respectively. Western 
blotting was used to quantify the change of P53, P21 and cleaved-PARP proteins in the AGS (e) and HGC27 cells (f), respectively. Caspase 3/7 assay 
was used to verify the apoptosis in response to cisplatin or 5-Fu in the stable AGS (g) and HGC27 cells (h), respectively
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that silencing S100A11 in GC cells may decrease the 
resistance to cisplatin or 5-FU resistance by inducing 
apoptosis.
S100A11 participates in multiple signalling pathways 
as indicated by high through antibody array
To determine the role of S100A11 in regulating cell sig-
nalling in GC cells globally, we conducted high through-
put Kinex antibody array using the stable cell lines 
following S100A11 knockdown. The regulated proteins, 
in response to the S100A11 knockdown in two paren-
tal cell lines, were compared using heatmap plotting 
(Fig.  6a). We further performed the signalling pathway 
enrichment analysis and observed that S100A11 is highly 
involved in the regulation of multiple signally pathways 
including MAPK3 (ERK1), PIK3CA, HGF/MET, CREBBP 
and MMP9 (Fig. 6b). The thumbnail images of the anti-
body array are shown in Additional file 1: Figure S1.
The expression profile of S100A11 is dimensionally close 
to S100A10 and S100A6
The HCPC analysis indicated that S100A11 is clustered as 
a distinctive factor that is dimensionally distant to most 
of the other S100 family members in GC. S100A11 con-
tributes predominantly to the first principal component 
(82.5%) while was distant from the second one (7.9%). 
Dimensionally, S100A11 is close to S100A6 and S100A10, 
as shown by both the PCA factor map and hierarchical 
clustering dendrogram, although S100A6 was marginally 
more similar to S100A11 compared to S100A10 (Addi-
tional file 2: Figure S2).
Discussion
In this study, we find that the overexpression of S100A11 
is associated with poor survival in GC patients as indi-
cated by Kaplan–Meier analysis. S100A11 transcript 
levels are upregulated in clinical GC samples compared 
with normal tissues. Additionally, S100A11 protein 
Fig. 6 The comparison of the key signalling transduction checkpoints by high throughput antibody array. a The heatmap plot showing the 
alteration of the signalling proteins after the S100A11 knockdown in the stable AGS and HGC27 cells. b The altered Protein–protein interaction 
network as a consequence of S100A11 knockdown was identified by enrichment analysis.
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level tends to be increased in advanced stages of GC or 
deeper tumour infiltration. S100A11 is a member of 
the S100 protein family which is composed of 21 mem-
bers which have structural similarity but are function-
ally noninterchangeable. The S100 family members have 
been considered as both intracellular calcium sensors 
and extracellular factors which regulate multiple cellular 
processes depending on its stimuli and effectors [29]. It 
is known that the S100A11 gene is located at 1q21.3, a 
site that is enriched with another seventeen S100 gene 
members. The dysregulation of S100A11 is linked with 
oncogenic activities including cancer progression. It has 
been observed to be overexpressed in many human solid 
tumours, such as pancreatic, melanoma, breast, ovarian 
and colorectal cancer [30–34]. Here we propose S100A11 
may play a positive role during the development and pro-
gression of GC.
Previous studies suggest that S100A11 plays a role in 
a variety of physiological processes in tumours which 
include regulation of cell differentiation, invasion, migra-
tion cell cycle and apoptosis [29]. We show herein that 
the knockdown of S100A11 results in diminished inva-
sion and migration capabilities of GC cells with the 
upregulation of epithelial markers and downregulation of 
mesenchymal markers. Thus, S100A11 may contribute to 
metastasis and poor prognosis in GC by promoting EMT. 
EMT is a biological programme that allows a polarized 
epithelial cell to undergo multiple changes that enable 
it to acquire a mesenchymal cell phenotype [35]. The 
acquisition of EMT features is crucial for carcinogenesis, 
invasion and metastasis. EMT is also a known risk fac-
tor that contributes to cancer recurrence and poor sur-
vival among patients with various solid cancers including 
breast [39], bladder [40], gastric [41], and colon cancer 
[42].
We demonstrate that the knockdown of S100A11 
upregulates the expression of E-cadherin. However, the 
correlation analysis using the TCGA data indicates that 
S100A11 positively correlates with E-cadherin. Unlike 
E-cadherin, N-cadherin is considered as a mesenchymal 
marker of EMT [39]. We show that the knockdown of 
S100A11 downregulates the expression of N-cadherin, 
while S100A11 negatively correlates with N-cadherin 
indicated by the analysis of TCGA data. This suggests that 
S100A11 may regulate the expression of E-cadherin/N-
cadherin at the protein level but not the transcript level. 
The downregulation of E-cad is a critical step in the EMT 
process [36], and E-cadherin is considered to be a tumour 
suppressor in gastric cancer [37, 38]. There has been no 
previous study on the role of S100A11 in the regulation 
of E-cadherin/N-cadherin in gastric cancer. However, 
a study on cervical cancer also suggests that S100A11 
upregulates N-cadherin while downregulates E-cadherin 
[40], implying that this may be common in several solid 
cancers.
In addition, we find that S100A11 downregulates 
MMP9 but upregulates MMP2 and MMP3. The human 
MMP protein family has 23 members and participates 
in cancer cell invasion and metastasis in diverse ways. 
Accumulating reports show that overexpression of cer-
tain MMPs (e.g. MMP2, MMP3 and MMP9) is associ-
ated with EMT during cancer initiation and progression 
[41]. We, therefore, propose that S100A11 may modulate 
the EMT programme by regulating the profiles of certain 
MMPs.
Here, we reveal that the knockdown of S100A11 leads 
to lower resistance to cisplatin or 5-FU-induced apopto-
sis in companies with an enhanced cleaved-PARP level in 
GC cells, and reduced rates of proliferation. Clinical data 
suggest that patients who positively respond to preop-
erative chemotherapy have a significantly longer survival 
time than non-responders [42]. However, tumour chem-
oresistance remains one of the most significant chal-
lenges to the successful treatment of GC [43]. Here our 
data unveil a new insight into the molecular mechanism 
whereby S100A11 plays a role in chemoresistance in GC.
The HCPC analysis indicates that S100A11 is indeed 
unique and distinctive when all of the 21 S100 family 
members are hierarchically clustered in GC. S100A11 
contributes predominantly to the first principal compo-
nent and keeps its centroid distance from most of the 
other members. Within two relatively close S100 neigh-
bours, high gene levels of both S100A6 and S100A10 
are associated with poor survival of patients with GC 
[44, 45]. They may promote malignant properties of gas-
tric cancer cells through modulating multiple signalling 
pathways such as various annexins and mTOR [45–48]. 
S100A11 may have the similarity of cellular functions 
by sharing the interaction of those protein effectors like 
S100A6 and S100A10 [49, 50].
The present study sheds light on the role of S100A11 
in tumor progression and chemoresistance in GC. The 
underlying mechanisms of this finding require further 
investigation. However, recent studies from other can-
cer types provide some possible leads. In hepatocel-
lular carcinoma, S100A11 is involved in inflammation 
which may contribute to cancer development [51]. Also, 
as a Ca2 + -binding protein, S100A11 may disrupt the 
repair of DNA double-strand breaks and genome integ-
rity by interacting with some key DNA strand exchange 
enzymes such as RAD51 [52]. Further, for translational 
research on a potential therapy by targeting S100A11, 
a humanised in vivo study may be vital to be developed 
for the first instance in order to mimic a bona fide GC 
environment.
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Conclusion
In summary, we reveal the role of S100A11 in GC and 
the relationship between S100A11 and chemotherapy 
resistance in human tumours. S100A11 is frequently 
overexpressed in both human GC tissues and cell lines, 
and positively correlates with poor survival in GC 
patients. Reduction of the expression of S100A11 in 
GC cells inhibits migration and invasion but decreases 
adhesion in GC cells. We observed that S100A11 func-
tions as a regulator of EMT and MMP proteins. Further, 
S100A11 knockdown leads to the decreased resist-
ance to cisplatin or 5-FU in GC cells. Taken together, 
this study suggests that S100A11 may present an inde-
pendent prognostic factor to predict the effectiveness 
of preoperative chemotherapy in patients with GC. 
To the best of our knowledge, this is the first report 
describing that S100A11-specific targeting potentially 
presents dual therapeutic benefits by not only control-
ling tumour progression but also sensitising a chemo-
therapeutic cytotoxic response (Schematic illustration 
in Additional file 3: Figure S3).
Abbreviations
GC: Gastric cancer; OS: Overall survival; HR: High Risk; HCPC: Hierarchical clus-
tering and principal component analysis; HR: Hazard ratio; EMT: Epithelial-mes-
enchymal transition; DMEM: Dulbecco’s modified Eagle’s medium; PPS: Post 
progression survival; FP: First progress survival; FACS: Fluorescence-activated 
cell sorting; 5-FU: 5-Fluorouracil; PVDF: Polyvinylidenedifluoride; TCGA : The 
Cancer Genome Atlas; STAD: Stomach Adenocarcinoma.
Supplementary Information
The online version contains supplementary material available at https:// doi. 
org/ 10. 1186/ s12935- 021- 01949-1.
Additional file 1: Figure S1. Images of the Kinex high throughput 
antibody array.
Additional file 2: Figure S2. Hierarchical Clustering on Principal Com-
ponents (HCPC) multivariate analysis of the human S100 family member 
genes in gastric cancer.
Additional file 3: Figure S3. Schematic illustration of the functions of 
S100A11 in gastric cancer cells.
Additional file 4: Table S1. Sequences of primer pairs for RT-PCR.
Acknowledgements
The authors thank CBS and Fiona Ruge for their technical assistance.
Authors’ contributions
YC and WGJ contributed to conceptualization. YC contributed to project 
administration, methodology, software including R programming and valida-
tion. YC, LL, ZL and JY contribute to formal analysis, data curation and inves-
tigation. YC contributed to validation. WGJ and JJ contributed to resources 
and supervision. YC and WGJ contributed to project administration. YC and LL 
contributed to the writing of the original draft preparation. YC, LL, JL and WGJ 
contributed to review and editing. WGJ, YC and LL contributed to funding 
acquisition. All authors read and approved the final manuscript.
Funding
The study was funded by the Realcan Fellowship and the Chinese Oversea 
Scholarship.
Availability of data and materials
All data generated or analyzed during this study are included in this published 
article and its supplementary information files.
Declarations
Ethics approval and consent to participate
The study was approved by the Ethics Committee of Peking University Beijing 
Cancer Hospital. All patients signed an informed consent form.
Consent for publication
All authors agreed on the manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1 Cardiff China Medical Research Collaborative, Cardiff University School 
of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK. 2 China-
Japan Friendship Hospital, Yinghuayuan East Street, Beijing 10029, China. 
3 Department of Pharmacy, Southern University of Science and Technology 
Hospital, Shenzhen 518055, China. 4 Department of General Surgery, Beijing 
Friendship Hospital, Capital Medical University, Beijing, China. 5 Beijing Key 
Laboratory of Cancer Invasion and Metastasis Research and National Clinical 
Research Center for Digestive Diseases, 95 Yong-an Road, Xi-Cheng District, 
Beijing 100050, China. 6 Key Laboratory of Carcinogenesis and Translational 
Research, Department of GI Surgery, Peking University Cancer Hospital 
and Institute, Beijing 100142, China. 
Received: 16 February 2021   Accepted: 22 April 2021
References
 1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global 
cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. https:// doi. org/ 
10. 3322/ caac. 21262.
 2. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric 
cancer. Lancet. 2020;396:635–48. https:// doi. org/ 10. 1016/ s0140- 6736(20) 
31288-5.
 3. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric 
cancer. Lancet (London, England). 2016;388:2654–64. https:// doi. org/ 10. 
1016/ s0140- 6736(16) 30354-3.
 4. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. 
Lancet (London, England). 2009;374:477–90. https:// doi. org/ 10. 1016/ 
s0140- 6736(09) 60617-6.
 5. Lee JH, Kim KM, Cheong JH, Noh SH. Current management and future 
strategies of gastric cancer. Yonsei Med J. 2012;53:248–57. https:// doi. org/ 
10. 3349/ ymj. 2012. 53.2. 248.
 6. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends 
Mol Med. 2006;12:440–50. https:// doi. org/ 10. 1016/j. molmed. 2006. 07. 007.
 7. Donato R. S100: a multigenic family of calcium-modulated proteins of 
the EF-hand type with intracellular and extracellular functional roles. Int J 
Biochem Cell Biol. 2001;33:637–68.
 8. Hao J, Wang K, Yue Y, Tian T, Xu A, Hao J, Xiao X, He D. Selective expres-
sion of S100A11 in lung cancer and its role in regulating proliferation of 
adenocarcinomas cells. Mol Cell Biochem. 2012;359:323–32. https:// doi. 
org/ 10. 1007/ s11010- 011- 1026-8.
 9. Wang G, Wang X, Wang S, Song H, Sun H, Yuan W, Cao B, Bai J, Fu S. 
Colorectal cancer progression correlates with upregulation of S100A11 
expression in tumor tissues. Int J Colorectal Dis. 2008;23:675–82. https:// 
doi. org/ 10. 1007/ s00384- 008- 0464-6.
 10. Ohuchida K, Mizumoto K, Ohhashi S, Yamaguchi H, Konomi H, Nagai 
E, Yamaguchi K, Tsuneyoshi M, Tanaka M. S100A11, a putative tumor 
Page 14 of 15Cui et al. Cancer Cell Int          (2021) 21:243 
suppressor gene, is overexpressed in pancreatic carcinogenesis. Clin Can-
cer Res. 2006;12:5417–22. https:// doi. org/ 10. 1158/ 1078- 0432. ccr- 06- 0222.
 11. Rehman I, Azzouzi AR, Cross SS, Deloulme JC, Catto JW, Wylde N, Larre 
S, Champigneuille J, Hamdy FC. Dysregulated expression of S100A11 
(calgizzarin) in prostate cancer and precursor lesions. Hum Pathol. 
2004;35:1385–91. https:// doi. org/ 10. 1016/j. humpa th. 2004. 07. 015.
 12. Chen H, Xu C, Jin Q, Liu Z. S100 protein family in human cancer. Am J 
Cancer Res. 2014;4:89–115.
 13. Niu Y, Shao Z, Wang H, Yang J, Zhang F, Luo Y, Xu L, Ding Y, Zhao L. LASP1-
S100A11 axis promotes colorectal cancer aggressiveness by modulating 
TGFbeta/Smad signaling. Sci Rep. 2016;6:26112. https:// doi. org/ 10. 1038/ 
srep2 6112.
 14. Lo JF, Yu CC, Chiou SH, Huang CY, Jan CI, Lin SC, Liu CJ, Hu WY, Yu YH. The 
epithelial-mesenchymal transition mediator S100A4 maintains cancer-
initiating cells in head and neck cancers. Can Res. 2011;71:1912–23. 
https:// doi. org/ 10. 1158/ 0008- 5472. can- 10- 2350.
 15. Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T, Nexo E. 
Down-regulation of S100C is associated with bladder cancer progression 
and poor survival. Clin Cancer Res. 2005;11:606–11.
 16. Xiao MB, Jiang F, Ni WK, Chen BY, Lu CH, Li XY, Ni RZ. High expression of 
S100A11 in pancreatic adenocarcinoma is an unfavorable prognostic 
marker. Med Oncol (Northwood, London, England). 2012;29:1886–91. 
https:// doi. org/ 10. 1007/ s12032- 011- 0058-y.
 17. Kondo A, Sakaguchi M, Makino E, Namba M, Okada S, Huh NH. Localiza-
tion of S100C immunoreactivity in various human tissues. Acta Med 
Okayama. 2002;56:31–4.
 18. Liu Y, Han X, Gao B. Knockdown of S100A11 expression suppresses ovar-
ian cancer cell growth and invasion. ExpTher Med. 2015;9:1460–4. https:// 
doi. org/ 10. 3892/ etm. 2015. 2257.
 19. Gorsler T, Murzik U, Ulbricht T, Hentschel J, Hemmerich P, Melle C. DNA 
damage-induced translocation of S100A11 into the nucleus regulates 
cell proliferation. BMC Cell Biol. 2010;11:100. https:// doi. org/ 10. 1186/ 
1471- 2121- 11- 100.
 20. Zagryazhskaya A, Surova O, Akbar NS, Allavena G, Gyuraszova K, Zborovs-
kaya IB, Tchevkina EM, Zhivotovsky B. Tudor staphylococcal nuclease 
drives chemoresistance of non-small cell lung carcinoma cells by regulat-
ing S100A11. Oncotarget. 2015;6:12156–73. https:// doi. org/ 10. 18632/ 
oncot arget. 3495.
 21. Cecil DL, Johnson K, Rediske J, Lotz M, Schmidt AM, Terkeltaub R. 
Inflammation-induced chondrocyte hypertrophy is driven by receptor for 
advanced glycation end products. J Immunol-. 2005;175:8296–302.
 22. Chang N, Sutherland C, Hesse E, Winkfein R, Wiehler WB, Pho M, Veil-
lette C, Li S, Wilson DP, Kiss E, et al. Identification of a novel interaction 
between the Ca(2+)-binding protein S100A11 and the Ca(2+)- and 
phospholipid-binding protein annexin A6. Am J Physiol Cell Physiol. 
2007;292:C1417-1430. https:// doi. org/ 10. 1152/ ajpce ll. 00439. 2006.
 23. Foertsch F, Teichmann N, Kob R, Hentschel J, Laubscher U, Melle C. 
S100A11 is involved in the regulation of the stability of cell cycle 
regulator p21(CIP1/WAF1) in human keratinocyte HaCaT cells. FEBS J. 
2013;280:3840–53. https:// doi. org/ 10. 1111/ febs. 12378.
 24. Murzik U, Hemmerich P, Weidtkamp-Peters S, Ulbricht T, Bussen W, 
Hentschel J, von Eggeling F, Melle C. Rad54B targeting to DNA double-
strand break repair sites requires complex formation with S100A11. 
MolBiol Cell. 2008;19:2926–35. https:// doi. org/ 10. 1091/ mbc. E07- 11- 1167.
 25. Bianchi R, Giambanco I, Arcuri C, Donato R. Subcellular localization of 
S100A11 (S100C) in LLC-PK1 renal cells: Calcium- and protein kinase 
c-dependent association of S100A11 with S100B and vimentin intermedi-
ate filaments. Microsc Res Tech. 2003;60:639–51. https:// doi. org/ 10. 1002/ 
jemt. 10305.
 26. Keese CR, Wegener J, Walker SR, Giaever I. Electrical wound-healing assay 
for cells in vitro. ProcNatlAcadSci USA. 2004;101:1554–9. https:// doi. org/ 
10. 1073/ pnas. 03075 88100.
 27. Lê S, Josse J, Husson F. FactoMineR: an R package for multivariate analysis. 
J Stat Softw. 2008;25:1–18.
 28. Kassambara, A., Mundt, F. Package ‘factoextra’. Extract and visualize the 
results of multivariate data analyses 2017; 76.
 29. Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer. Nat Rev 
Cancer. 2015;15:96–109. https:// doi. org/ 10. 1038/ nrc38 93.
 30. Anania MC, Miranda C, Vizioli MG, Mazzoni M, Cleris L, Pagliardini S, 
Manenti G, Borrello MG, Pierotti MA, Greco A. S100A11 overexpression 
contributes to the malignant phenotype of papillary thyroid carcinoma. 
J ClinEndocrinolMetab. 2013;98:E1591-1600. https:// doi. org/ 10. 1210/ jc. 
2013- 1652.
 31. Koh SA, Lee KH. HGF-mediated S100A11 overexpression enhances prolif-
eration and invasion of gastric cancer. Am J Transl Res. 2018;10:3385–94.
 32. Mitsui Y, Tomonobu N, Watanabe M, Kinoshita R, Sumardika IW, Youyi C, 
Murata H, Yamamoto KI, Sadahira T, Rodrigo AGH, et al. Upregulation of 
mobility in pancreatic cancer cells by secreted S100A11 through activa-
tion of surrounding fibroblasts. Oncol Res. 2019;27:945–56. https:// doi. 
org/ 10. 3727/ 09650 4019x 15555 40878 4978.
 33. Sato H, Sakaguchi M, Yamamoto H, Tomida S, Aoe K, Shien K, Yoshioka 
T, Namba K, Torigoe H, Soh J, et al. Therapeutic potential of targeting 
S100A11 in malignant pleural mesothelioma. Oncogenesis. 2018;7:11. 
https:// doi. org/ 10. 1038/ s41389- 017- 0017-3.
 34. Tu Y, Xie P, Du X, Fan L, Bao Z, Sun G, Zhao P, Chao H, Li C, Zeng A, et al. 
S100A11 functions as novel oncogene in glioblastoma via S100A11/
ANXA2/NF-κB positive feedback loop. J Cell Mol Med. 2019;23:6907–18. 
https:// doi. org/ 10. 1111/ jcmm. 14574.
 35. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-
mesenchymal transition and implications for cancer. Nat Rev Mol Cell 
Biol. 2019;20:69–84. https:// doi. org/ 10. 1038/ s41580- 018- 0080-4.
 36. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating 
cancer stem cells—an integrated concept of malignant tumour progres-
sion. Nat Rev Cancer. 2005;5:744–9. https:// doi. org/ 10. 1038/ nrc16 94.
 37 Bruner HC, Derksen PWB. Loss of E-cadherin-dependent cell-cell adhe-
sion and the development and progression of cancer. Cold Spring 
HarbPerspect Biol. 2018. https:// doi. org/ 10. 1101/ cshpe rspect. a0293 30.
 38. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite 
H, Scoular R, Miller A, Reeve AE. E-cadherin germline mutations in familial 
gastric cancer. Nature. 1998;392:402–5. https:// doi. org/ 10. 1038/ 32918.
 39. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin 
dysfunction promote tumor progression? Oncogene. 2008;27:6920–9. 
https:// doi. org/ 10. 1038/ onc. 2008. 343.
 40. Meng M, Sang L, Wang X. S100 calcium binding protein A11 (S100A11) 
promotes the proliferation, migration and invasion of cervical can-
cer cells, and activates Wnt/β-catenin signaling. Onco Targets Ther. 
2019;12:8675–85. https:// doi. org/ 10. 2147/ ott. S2252 48.
 41. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in 
cancer progression. Nat Rev Cancer. 2002;2:161–74. https:// doi. org/ 10. 
1038/ nrc745.
 42. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden 
of cancer: priorities for prevention. Carcinogenesis. 2010;31:100–10. 
https:// doi. org/ 10. 1093/ carcin/ bgp263.
 43. Cheong JH, Yang HK, Kim H, Kim WH, Kim YW, Kook MC, Park YK, Kim HH, 
Lee HS, Lee KH, et al. Predictive test for chemotherapy response in resect-
able gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncol. 
2018;19:629–38. https:// doi. org/ 10. 1016/ s1470- 2045(18) 30108-6.
 44. Wang XH, Zhang LH, Zhong XY, Xing XF, Liu YQ, Niu ZJ, Peng Y, Du H, 
Zhang GG, Hu Y, et al. S100A6 overexpression is associated with poor 
prognosis and is epigenetically up-regulated in gastric cancer. Am J 
Pathol. 2010;177:586–97. https:// doi. org/ 10. 2353/ ajpath. 2010. 091217.
 45. Li Y, Li XY, Li LX, Zhou RC, Sikong Y, Gu X, Jin BY, Li B, Li YQ, Zuo XL. 
S100A10 accelerates aerobic glycolysis and malignant growth by 
activating mTOR-signaling pathway in gastric cancer. Front Cell Dev Biol. 
2020;8:559486. https:// doi. org/ 10. 3389/ fcell. 2020. 559486.
 46. Lu H, Xie Y, Tran L, Lan J, Yang Y, Murugan NL, Wang R, Wang YJ, Semenza 
GL. Chemotherapy-induced S100A10 recruits KDM6A to facilitate 
OCT4-mediated breast cancer stemness. J Clin Invest. 2020;130:4607–23. 
https:// doi. org/ 10. 1172/ jci13 8577.
 47. Donato R, Sorci G, Giambanco I. S100A6 protein: functional roles. Cell Mol 
Life Sci. 2017;74:2749–60. https:// doi. org/ 10. 1007/ s00018- 017- 2526-9.
 48. Nedjadi T, Kitteringham N, Campbell F, Jenkins RE, Park BK, Navarro P, Ash-
croft F, Tepikin A, Neoptolemos JP, Costello E. S100A6 binds to annexin 2 
in pancreatic cancer cells and promotes pancreatic cancer cell motility. Br 
J Cancer. 2009;101:1145–54. https:// doi. org/ 10. 1038/ sj. bjc. 66052 89.
 49. Jaiswal JK, Lauritzen SP, Scheffer L, Sakaguchi M, Bunkenborg J, Simon 
SM, Kallunki T, Jäättelä M, Nylandsted J. S100A11 is required for efficient 
plasma membrane repair and survival of invasive cancer cells. Nat Com-
mun. 2014;5:3795. https:// doi. org/ 10. 1038/ ncomm s4795.
 50. Teng F, Jiang J, Zhang J, Yuan Y, Li K, Zhou B, Zhou X, Liu W, Zhang P, 
Liu D, et al. The S100 calcium-binding protein A11 promotes hepatic 
Page 15 of 15Cui et al. Cancer Cell Int          (2021) 21:243  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
steatosis through RAGE-mediated AKT-mTOR signaling. Metabolism. 
2021;117:154725. https:// doi. org/ 10. 1016/j. metab ol. 2021. 154725.
 51. Sobolewski C, Abegg D, Berthou F, Dolicka D, Calo N, Sempoux C, 
Fournier M, Maeder C, Ay AS, Clavien PA, et al. S100A11/ANXA2 belongs 
to a tumour suppressor/oncogene network deregulated early with 
steatosis and involved in inflammation and hepatocellular carci-
noma development. Gut. 2020;69:1841–54. https:// doi. org/ 10. 1136/ 
gutjnl- 2019- 319019.
 52. Foertsch F, Melle C. Analysis of S100A11 in DNA Damage Repair. Methods 
MolBiol. 2019;1929:447–60. https:// doi. org/ 10. 1007/ 978-1- 4939- 9030-6_ 
28.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
